{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:00:18Z","timestamp":1787587218486,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["22 170"],"award-info":[{"award-number":["22 170"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006388","name":"H\u00f4pitaux Universitaires de Gen\u00e8ve","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Seasonal influenza virus leads to more than half a million deaths each year worldwide. Due to its capacity to evolve, it is considered the most likely pathogen to cause a future pandemic. Antiviral treatment options are currently limited, with the most widely used drugs being neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir marboxil. In adult hospitalized patients, due to the lack of placebo-controlled trials, current available evidence on antiviral treatment benefits is essentially based on observational studies. A placebo-controlled clinical trial is needed to fill this knowledge gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is an investigator-initiated, randomized, triple-blind, placebo-controlled, superiority, multi-center trial to assess the clinical efficacy of single-dose baloxavir in decreasing time to clinical improvement in adult immunocompetent patients hospitalized with influenza. Patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009484) with confirmed, severe infection (NEWS2 score\u2009\u2265\u20094) will be recruited over three influenza seasons in four large Swiss hospitals. Primary outcome: time to clinical improvement (in hours), calculated from treatment administration until NEWS2 score\u2009\u2264\u20092 maintained for 24\u00a0h or until hospital discharge, whichever comes first. The primary outcome is calculated in all patients independently of the duration of symptoms at treatment administration, as well as in participants treated early (&lt;72\u00a0h) post onset of symptoms. The main secondary outcomes are the risk of serious influenza complications, length of hospitalization, and difference in viral load at D3 post-treatment administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial\u2019s results, whether positive or negative, will impact clinical guidance. If baloxavir\u2019s clinical benefit is demonstrated, a single-dose pill would be the easiest implementable treatment option in case of large seasonal outbreaks or a new influenza pandemic. If a clear treatment benefit is not shown, antiviral treatment administration in the hospitalized patient population could be reconsidered to prevent unnecessary medication, lower the risk of resistance development linked to treatment overuse, and ultimately save unnecessary treatment-related expenses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov NCT06653569. Registered on October 22, 2024,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06653569?term=NCT06653569&amp;rank=1\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT06653569?term=NCT06653569&amp;rank=1<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09248-0","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:18:51Z","timestamp":1763983131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiviral treatment in adult patients hospitalized for influenza: study protocol for a multi-center, randomized, placebo-controlled trial on the efficacy of baloxavir marboxil to reduce time to clinical improvement and the risk for severe complications (the INFLUENT trial)"],"prefix":"10.1186","volume":"26","author":[{"given":"Krisztina","family":"Hosszu-Fellous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita Goncalves","family":"Cabecinhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Schibler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Prendki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Pouillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Slankamenac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Alexandre","family":"Bart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enos","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Mombelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas J.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-5069","authenticated-orcid":false,"given":"Pauline","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"9248_CR1","unstructured":"Federal Office of Public Health. Seasonal flu. 2023 Dec 14 [cited 2025 Mar 14]. https:\/\/www.bag.admin.ch\/bag\/fr\/home\/krankheiten\/krankheiten-im-ueberblick\/grippe.html."},{"issue":"4","key":"9248_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00705-018-3708-y","volume":"163","author":"B Kumar","year":"2018","unstructured":"Kumar B, Asha K, Khanna M, Ronsard L, Meseko CA, Sanicas M. The emerging influenza virus threat: status and new prospects for its therapy and control. Arch Virol. 2018;163(4):831\u201344. https:\/\/doi.org\/10.1007\/s00705-018-3708-y.","journal-title":"Arch Virol"},{"key":"9248_CR3","unstructured":"World Health Organization. Ongoing avian influenza outbreaks in animals pose risk to humans. Situation analysis and advice to countries from FAO, WHO, WOAH. 2023 Jul 12 [cited 2025 Mar 14]. https:\/\/www.who.int"},{"issue":"6","key":"9248_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3201\/eid2206.151037","volume":"22","author":"AC Hurt","year":"2016","unstructured":"Hurt AC, Kelly H. Debate regarding oseltamivir use for seasonal and pandemic influenza. Emerg Infect Dis. 2016;22(6):949\u201355. https:\/\/doi.org\/10.3201\/eid2206.151037.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"9248_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s0140-6736(22)00982-5","volume":"400","author":"TM Uyeki","year":"2022","unstructured":"Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. Lancet. 2022;400(1):693\u2013706. https:\/\/doi.org\/10.1016\/s0140-6736(22)00982-5.","journal-title":"Lancet"},{"key":"9248_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd008965","author":"T Jefferson","year":"2014","unstructured":"Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children - a review of clinical study reports. Cochrane Database Syst Rev. 2014Apr 10. https:\/\/doi.org\/10.1002\/14651858.cd008965.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"9248_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s2213-2600(14)70041-4","volume":"2","author":"SG Muthuri","year":"2014","unstructured":"Muthuri SG, Venkatesan S, Myles P, Leonardi-Bee J, Khuwaitir TSA, Al Mamun A, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014May 1;2(5):395\u2013404. https:\/\/doi.org\/10.1016\/s2213-2600(14)70041-4.","journal-title":"Lancet Respir Med"},{"key":"9248_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz152","author":"S Venkatesan","year":"2020","unstructured":"Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, et al. Neuraminidase inhibitors and hospital length of stay: a meta-analysis of individual participant data to determine treatment effectiveness among patients hospitalized with nonfatal 2009 pandemic influenza A(H1N1) virus infection. J Infect Dis. 2020Jan 14. https:\/\/doi.org\/10.1093\/infdis\/jiz152.","journal-title":"J Infect Dis"},{"issue":"9","key":"9248_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/cid\/cis642","volume":"55","author":"N Lee","year":"2012","unstructured":"Lee N, Ison MG. Editorial commentary: \u201clate\u201d treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never? Clin Infect Dis. 2012;55(9):1205\u20138. https:\/\/doi.org\/10.1093\/cid\/cis642.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"9248_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf058","volume":"12","author":"H Pott","year":"2025","unstructured":"Pott H, Andrew MK, Shaffelburg Z, Nichols MK, Ye L, ElSherif M, et al. Oseltamivir reduces 30-day mortality in older adults with influenza: a pooled analysis from the 2012\u20132019 serious outcomes surveillance network of the Canadian immunization research network. Open Forum Infect Dis. 2025;12(2):ofaf058. https:\/\/doi.org\/10.1093\/ofid\/ofaf058.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"9248_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/cid\/ciae427","volume":"80","author":"MW Tenforde","year":"2025","unstructured":"Tenforde MW, Noah KP, O\u2019Halloran AC, Kirley PD, Hoover C, Alden NB, et al. Timing of influenza antiviral therapy and risk of death in adults hospitalized with influenza-associated pneumonia, Influenza Hospitalization Surveillance Network (FluSurv-NET), 2012\u20132019. Clin Infect Dis. 2025;80(2):461\u20138. https:\/\/doi.org\/10.1093\/cid\/ciae427.","journal-title":"Clin Infect Dis"},{"issue":"10454","key":"9248_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0140-6736(24)01307-2","volume":"404","author":"Y Gao","year":"2024","unstructured":"Gao Y, Guyatt G, Uyeki TM, Liu M, Chen Y, Zhao Y, et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;404(10454):753\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(24)01307-2.","journal-title":"Lancet"},{"key":"9248_CR13","unstructured":"World Health Organization. Clinical practice guidelines for influenza. 2024 [cited 2025 Mar 14]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/378872\/9789240097759-eng.pdf?sequence=1."},{"issue":"10","key":"9248_CR14","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/jac\/dkaa252","volume":"75","author":"S Shah","year":"2020","unstructured":"Shah S, McManus D, Bejou N, Tirmizi S, Rouse GE, Lemieux SM, et al. Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with influenza A. J Antimicrob Chemother. 2020;75(10):3015\u201322. https:\/\/doi.org\/10.1093\/jac\/dkaa252.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"9248_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","volume":"14","author":"J Dunning","year":"2014","unstructured":"Dunning J, Baillie JK, Cao B, Hayden FG, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis. 2014;14(12):1259\u201370. https:\/\/doi.org\/10.1016\/S1473-3099(14)70821-7.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"9248_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","volume":"22","author":"D Kumar","year":"2022","unstructured":"Kumar D, Ison MG, Mira JP, Welte T, Hwan Ha J, Hui DS, et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. 2022;22(5):718\u201330. https:\/\/doi.org\/10.1016\/S1473-3099(21)00469-2.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"9248_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"issue":"1","key":"9248_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","volume":"22","author":"E Stolk","year":"2019","unstructured":"Stolk E, Ludwig K, Rand K, van Hout B, Ramos-Go\u00f1i JM. Overview, update, and lessons learned from the International EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol. Value Health. 2019;22(1):23\u201330. https:\/\/doi.org\/10.1016\/j.jval.2018.05.010.","journal-title":"Value Health"},{"key":"9248_CR19","unstructured":"World Health Organization. Summary of polymerase acidic (PA) protein amino acid substitutions analysed for their effects on baloxavir susceptibility. 2023 Mar 7 [cited 2025 Mar 14]. https:\/\/www.who.int\/publications\/m\/item\/summary-of-polymerase-acidic-(pa)-protein-amino-acid-substitutions-analysed-for-their-effects-on-baloxavir-susceptibility."},{"key":"9248_CR20","unstructured":"European Medicines Agency. ICH E9 statistical principles for clinical trials: step 5. EMA; [cited 2025 Oct 6]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09248-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:18:55Z","timestamp":1763983135000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09248-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9248"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09248-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol has been reviewed and approved by the competent ethics committee (Commission d\u2019\u00e9thique et de la recherche CCER de Gen\u00e8ve), CCER 2024-01535. Written informed consent to participate is obtained from all participants or their close family member in case of incapacity to consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"BM received research funds from Moderna Inc. and is a consultant for Rocketvax AG. The other authors declare that they have no competing interests (Laurent Kaiser, Antoine Poncet, Virginie Prendki, Muller Nicolas, Pauline Vetter, Krisztina Hosszu-Fellous, Sebastian Carballo, Manuel Oriol, Matteo Mombelli, Manuel Schibler, Ana Rita Goncalves, Angela Huttner, Enos Bernasconi, Mathias Pouillon, Pierre-Alexandre Bart, Ksenija Slankamenac).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"538"}}